Dassault Systèmes SE will buy drug trial software maker ArisGlobal for as much as $2 billion as the French company expands its push into life sciences, according to Bloomberg.
The deal adds a software provider focused on drug trials to Dassault Systèmes' portfolio as it broadens its life sciences business.
STOCKS | Dassault Systèmes to Buy ArisGlobal for Up to $2 Billion
2026-07-23 05:16:40
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
STOCKS | Hyundai Motor Profit Misses Estimates as Sales Slump
